HAM
CRSP icon

Hedges Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Hedges Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$564 – 113
2024
Q3 		$564 Buy
+12
New +$609 ﹤0.01% 116

Other funds holding CRSP

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Hedges Asset Management's CRSP Position: Q2 2026 in Review

Hedges Asset Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 24,575 shares worth $1.34M. The stake represents 0.88% of the portfolio and ranks #35 among its holdings. This is a return to the name: Hedges Asset Management previously reported a position in CRSP as recently as Q4 2025.

Hedges Asset Management first reported a position in CRSP in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.46M in Q3 2025. 181 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Hedges Asset Management held 24,575 shares of CRISPR Therapeutics worth $1.34M as of Q2 2026.
  • CRISPR Therapeutics was a new Hedges Asset Management position in Q2 2026.
  • CRISPR Therapeutics made up 0.88% of Hedges Asset Management's portfolio in Q2 2026, its #35 holding.
  • Hedges Asset Management first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Hedges Asset Management's CRISPR Therapeutics position peaked at $1.46M in Q3 2025.
  • 181 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Hedges Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.